ReviewJournal of advanced research2026
Developing chemical reprogramming strategies of non-hepatocytes for liver regeneration.
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver injury and the ensuing regenerative processes exert a profound impact on treatment outcomes. Conventional pharmacotherapy, nutritional adjuncts, and invasive interventions, despite their frequent utilization, often prove inefficacious. Chemical reprogramming, which employs small molecules to emulate extrinsic signaling cues, emerges as a promising therapeutic strategy for liver regeneration, analogous to the developmental processes governing cellular fate. However, its application in hepatic repair necessitates systematic integration. AIM OF REVIEW: This review synthesizes the role of chemical reprogramming in liver regeneration research. It first delineates the mechanisms underlying chemical reprogramming, emphasizing the pivotal role of small molecules in facilitating hepatic regeneration through the modulation of specific signaling pathways and epigenetic modifications. Additionally, it details the derivation of hepatocyte-like cells via chemical reprogramming within the realm of tissue engineering. The review further explores the role of chemical reprogramming in promoting in vivo liver repair and regeneration, particularly within the context of combinatorial therapeutic strategies. KEY SCIENTIFIC CONCEPTS OF REVIEW: Chemical reprogramming induces the reprogramming of non-hepatic cells into hepatocyte-like cells through the precise regulation of cellular signaling pathways and epigenetic modifications by small molecules, thereby achieving cellular composition remodeling in injured livers. Current liver regeneration strategies rely on the modulation of endogenous regenerative capacity and cell-based therapies; thus, elucidating the regenerative and reparative roles of chemical reprogramming in liver injury is imperative. Addressing the inherent challenges of chemical reprogramming in hepatic regeneration is also underscored.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.